Investing in AN2 Therapeutics (ANTX) is widely characterized as a high-risk, speculative opportunity rather than a conventional core investment. As a clinical-stage biopharmaceutical enterprise focused on developing novel treatments for rare and infectious diseases, its long-term financial success depends entirely on successful clinical trial outcomes, regulatory approvals, and eventual commercialization. Investors lacking a high risk tolerance should approach clinical-stage biotechnology equities with extreme caution.